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ABSTRACT  
Background: The hypermetabolic state after severe burns is a major problem that can lead to 
several pathophysiological changes and produce multiple sequelae. Adrenergic blockade has 
been widely used to reverse these changes and improve outcomes in burned patients, but has not 
been rigorously evaluated. The aim of this systematic review is to investigate the efficacy and 
safety of use of adrenergic blockade post burn injury. 
Methods: The databases MEDLINE via OVID, Pubmed, EMBASE, CINAHL, Cochrane 
Library and Web of Science were searched from inception to December 2014 with search terms 
including “burns” and “Beta-Blockers” with appropriate synonyms. Articles were restricted to 
those published in English, French or Spanish. Randomized controlled trials, non-randomized 
controlled trials and systematic reviews were screened. After an independent screening and full 
text review, ten articles were selected and an appraisal of risk of bias was performed. 
Results: From 182 articles screened, nine randomized controlled trials and one non-randomized 
controlled trial met the inclusion criteria. Pooled analyses were performed to calculate effect 
sizes and 95% confidence intervals. There was a positive effect favouring propranolol use that 
significantly decreased resting energy expenditure (g=-0.64; 95% CI -0.8,-0.5; p<0.001) trunk fat 
(g=-0.3; 95% CI -0.4,-0.1; p<0.001); improved peripheral lean mass (g=0.45; CI 0.3, 0.6; 
p<0.001) and insulin resistance (g=-1.35; 95% CI -2.0,-0.6; p<0.001). Occurrence of adverse 
events was not significantly different between treated patients and controls.  
Conclusions: Limited evidence suggests beneficial effects of propranolol post burn injury and its 
use appears safe. However further trials on adult population with a broader range of outcome 
measures are warranted. 
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BACKGROUND 
Worldwide, there were nearly 11 million severe burn injuries requiring medical care in 2004 (1). 
Mortality due to burn injuries has been reduced from an age-standardised death rate (per 
100,000) of 5.9 in 1990 to 3.5 in 2013. This represents a median change of -41.9 (-50.85 to -
29.74) % in the whole period (2) and as a result, a burn injury is emerging as a challenging 
chronic disease, with 20 (12-32) years living with disability per 100,000 individuals in the world 
population (3).  
Changes to systemic metabolism drive the majority of the pathological problems. The 
hypermetabolic response following burns is characterized by an elevated metabolic rate, 
hyperdynamic circulation, increased oxygen and glucose consumption, muscle and bone 
hypercatabolism. Evidence also suggests higher rates of infection even after three years post burn 
(4).  
Catecholamines play a role as primary mediators of the hypermetabolic response in severe burns 
(5). Early after the burn injury, a 10-fold increase in plasma catecholamine concentration can be 
observed in patients and this dramatic rise could explain the increased muscle protein catabolism 
and the elevated metabolic rate (6). 
Several pharmacological studies involving anabolic steroids, recombinant human growth 
hormone (rhGH), insulin, and metformin have examined the efficacy of these drugs on the 
reduction of hypermetabolic response post burn injury (7, 8). Similarly, adrenergic blockade, 
specifically the non-selective adrenergic beta antagonist propranolol, has been utilized to 
minimise the effects of the elevated level of plasma catecholamine concentrations. This 
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hypothetically results in an anticatabolic effect thereby reducing the catecholamine-induced 
hypermetabolic response (7).  
Furthermore, administration of beta-antagonists may produce short (immunosuppression in acute 
stress conditions or haemodynamic compromise) or long term side effects, such as attenuation of 
the immune function (9, 10). However, to date, there has not been a systematic evaluation of the 
benefits and safety of propranolol following burn injury.  
Therefore, the purpose of this systematic review is to assess the quality of evidence supporting 
the efficacy and safety of use of beta-adrenergic blockade in adults and children affected by burn 
injuries. 
 
METHODS 
A protocol for the systematic review was created (see protocol, Supplemental Digital Content 1, 
http://links.lww.com/TA/A672) and registered at PROSPERO database (registration number 
CRD42014015115). The PRISMA statement (11, 12) was followed to assure the quality of 
reporting (see checklist, Supplemental Digital Content 2, http://links.lww.com/TA/A673). 
Paper Identification and Selection 
To search the databases, a population, intervention, comparison, outcomes and study design 
(PICOS) approach was performed to select and define keywords. Population was defined as 
adults or children in any phase of burn injury. Beta Blockers in general or propranolol as the 
specific drug were defined as the exclusive intervention; consequently, combined intervention 
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studies were excluded. We did not make comparisons with any other treatment and outcomes 
were defined as any endpoint showing changes in efficacy and safety after intervention.  
Studies were identified by searching Medline via OVID, Pubmed, CINAHL, Cochrane Library, 
Embase and Web of Science databases using the key words “Burn”, “Burns”, “Burned”, “Burn 
injury” or “Thermal Injury” for population and “Beta-Blockers”, “Adrenergic Beta-Antagonists” 
or “Propranolol” for intervention. The searching process was restricted to studies performed in 
humans and by study design (Systematic Reviews, Randomized Controlled Trials or Non-
Randomized Controlled Trials). The searching period was from database inception until 
December 2014 and restrictions were applied to select articles published in English, French or 
Spanish languages (see search strategy for PubMed Supplemental Digital Content 3, 
http://links.lww.com/TA/A674). 
Disagreements between reviewers (OF, JP) were resolved by consensus by a third reviewer (KS). 
Citation tracking and key author searches were also completed with no further studies identified 
(Figure 1). 
A data extraction sheet was developed, and one author (OF) extracted the data from selected 
articles, completed the data sheet and tabulated the information. Five authors were contacted to 
request further information. One author provided figures that had been presented in graphical 
form in the published report. Information was extracted from each article including: a) 
characteristics of participants (age, gender, severity of injury) b) modality of treatment (length, 
dose, administration via) and c) outcome measures. 
To appraise the risk of bias on selected reports, two reviewers (OF, JP) working independently, 
used a modified and updated version of the method for assessing the quality of Randomized 
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Controlled Trials published by Chalmers et al (1981) (13). This scale determined the adequacy of 
randomization process, allocation concealment, use of placebo medication in the control group, 
blinding of patients and researchers and the quality of reporting. 
Data Analysis 
A quantitative approach was used to analyse the data at a group level, if there were two or 
greater trials with homogenous outcomes. To compare results between trials, for continuous 
outcomes the unbiased effect size estimators (Hedges g) with 95% confidence intervals was 
calculated, using Comprehensive Meta-analysis™ software. Dichotomous outcomes were 
expressed as risk ratios with 95% confidence intervals. The data was pooled using the fixed 
effects model, however when heterogeneity was statistically significant (Q statistic p<0.01), the 
data was re-analysed using the random effects model.  
 
RESULTS 
The searching of the six databases provided a total of 282 citations. After duplicates were 
removed, 182 references were screened by two reviewers (OF, JP) using title and abstract 
information. One hundred and fifty three were discarded because they did not match the 
inclusion criteria.  Twenty nine were reviewed in full text to check eligibility. Nineteen studies 
were excluded in this phase (thirteen because design did not match inclusion criteria, three for 
using a combined intervention, two because participants did not match inclusion criteria and one 
conference abstract where the outcomes assessed were not relevant for this systematic review) 
(Figure 1).  Ten studies published between 2001 and 2012 were finally selected for the review, 
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nine of them were randomized controlled trials and one was a non-randomized controlled trial 
(14). No current systematic reviews on this topic were found.  
Intervention 
The length of the intervention ie beta-adrenergic blockade varied from ten days to twelve months 
with the median time of 21 days. Treatment was started from 24 hours to twelve days post burn 
injury. All trials used propranolol as the adrenergic-blockade agent. Dose, frequency and 
administration route varied among the selected studies (Table 1).  
Demographics and setting 
The included studies recruited a total number of 451 patients (range 4 to 125 patients) in the 
treatment arm, and 611 (range 4 to 215 patients) in the control arm. Seven studies (15-21) were 
completed in the paediatric population, one involved exclusively adults (22) and the remaining 
two studies (14, 23) used both paediatric and adult subjects.  All trials were performed in single-
centre settings and eight out of ten trials were performed in the same paediatric burn research 
centre. Detailed demographic data of the included studies can be observed in Table 1. 
Quality assessment 
The risk of bias for each study is detailed in Supplemental Digital Content 4 (see risk of bias, 
Supplemental Digital Content 4, http://links.lww.com/TA/A675). Of nine items analysed, three 
(random sequence generation, appropriate statistical analysis and complete non-selective 
reporting) were completed by 90% of the studies selected. Eight of ten studies advised of the  
selection description and reject log, while only 30% reported complete outcome data and figures 
(14, 19, 22). Only one (22) of 10 studies was explicit in use of blinding methods for both patients 
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and personnel. Assessor blinding was reported for one study (22), whilst allocation concealment 
and an a priori estimation of sample size were not reported by any study included in this 
systematic review. Only four studies (15, 17, 20, 22) reported using a placebo medication for the 
control group. 
As eight out of ten selected studies were completed in the same centre and trials had different 
outcomes and methodology, completing meta-analysis for the majority of measures was difficult. 
Outcome Measures 
Cardiac effects  
Heart rate – percentage change, percentage of predicted and absolute values   
From ten studies incorporated in this review, changes in heart rate post propranolol treatment 
were reported in five trials (18, 19, 21-23). Two studies (18, 21) found a decrease of 18-20% in 
the treatment group compared to controls (Table 2). 
Herndon et al (19), examined heart rate expressed as a percentage of predicted according to 
reference values in a paediatric population. Data reported at four different time points was used 
to calculate effect sizes using the fixed effect model (i²=0.00, Q= 2.4, p=0.493). There was a 
significant reduction in predicted heart rate at various time points favouring propranolol (pooled 
Hedges’s g=-0.258; 95% confidence interval -0.4, -0.1; p=0.001) (see Supplemental Digital 
Content 5, http://links.lww.com/TA/A676, heart rate % predicted forest plot graph). 
Heart rate measured by mean beats per minute (bpm) was examined in two studies performed in 
paediatric and adult populations (22, 23). Mohammadi et al (22) in an adult population reported a 
significantly decrease in heart rate after propranolol treatment, while Morio et al (23) in subjects 
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with ages ranged from 5.8 to 56.5 years (mean 21.7±18.9 years) also demonstrated a significant 
decrease associated to propranolol administration (Table 2). 
Cardiac Output 
Cardiac Output (% of predicted) was included as an outcome measure in one paediatric study 
(21) showing  a decrease favouring the intervention group (p<0.05) (Table 2). 
Metabolic outcome measures 
Liver Size 
Incidence of increased liver size was investigated in one study (15) to evaluate the efficacy of 
propranolol on reducing hepatomegaly after burn injury. From 49 children analysed receiving a 
placebo, 39 (80%) showed an increase in liver size compared to 5 (14%) in the propranolol 
group. Difference between groups was statistically significant χ² (1, N=85) = 35.87, p<0.01 
(Table 2). 
Metabolic Rate 
Five studies, all performed in a paediatric population (16-20)  included metabolic rate as a 
variable and all of them used resting energy expenditure (REE) as the outcome measure. One 
study (17) did not report the results obtained in this outcome, while another one (16) did not 
provide figures but reports a significant decrease in REE after propranolol use (p<0.05).  
Herndon et al. (18) reported REE as mean change in kcal/day and found a significant decrease in 
the propranolol group compared to controls (p=0.001). Detailed data is available in Table 2. 
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Jeschke et al (20) in varied treatment times found a significant effect (p<0.05) of propranolol 
administration on reduction of metabolic rate (Table 2). 
One paediatric study (19) calculated REE as a percentage of predicted from Harris-Benedict 
equations at different time points.  A fixed effects model was used to pool data (i²=46.1, Q=5.5, 
p=0.134) and a significant decrease in REE at each time point was found favouring propranolol 
use (Figure 2). 
From the ten studies included in this review, one used oxygen consumption (ml/min) as an 
outcome measure (18), finding a significant decrease (p=0.002) in propranolol treated children 
compared with controls (Table 2). 
Muscle wasting and body composition 
Protein kinetics  
Muscle protein net balance was measured in two paediatric studies (17, 18) showing a significant 
improvement in protein net balance after propranolol administration (Table 2).  
Additionally, Herndon et al (18) reported a trend towards significance in muscle protein 
synthesis (p=0.07) but no significant effect on muscle protein breakdown (p=0.2) after two 
weeks of propranolol treatment in children. Detailed data is shown in Table 2. 
Body composition 
Body composition was measured in a paediatric population in three studies (15, 18, 19) by 
whole-body potassium scanning or dual-energy x-ray absorptiometry using lean body mass, 
peripheral lean mass, fat free mass, total body fat and trunk fat as outcomes.  
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Lean body mass was included in two studies (15, 18) as an outcome measure. One study (15) 
described no significant change between the propranolol group and controls while Herndon et al. 
(18) found statistically significant improvements (p=0.01) post propranolol treatment.  
Two studies (15, 18) incorporated fat free mass (FFM) as an outcome measure with conflicting 
results. Barrow et al (15) reported non-significant decreases between groups, while Herndon et al 
(18) found a significant difference (p=0.003) in loss of FFM between the control (9%) and 
propranolol group (1%).  
Total body fat was measured in one study (15), with  no statistically significant effects found 
between the propranolol group and controls.  
Two studies (15, 19) examined trunk fat as an outcome measure and one (19) provided data at 
four different time points. A fixed-effects model (i²=0.000, Q=1.261, p=0.73) found a significant 
reduction in trunk fat favouring propranolol use over time (Figure 3). Barrow et al (15) also 
obtained trunk fat measures, with no significance between groups.  
Of ten studies selected, only one (19) investigated peripheral lean mass as one of the outcome 
measures for body composition and provided data obtained at four different time points. To 
illustrate the over time, effect sizes using a a fixed-effects model (i²=0.000, Q=0.08, p=0.99) 
were calculated and a significant improvement was found after propranolol treatment (Figure 4). 
Blood, plasma, serum hypermetabolism markers 
Insulin resistance 
Ackay et al (14) investigated changes in insulin resistance after one and two weeks of adrenergic 
blockade treatment in a mixed sample of children and adults. Data was pooled using a fixed-
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
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effects model (i²=0.000, Q=0.3, p=0.55) and a significant decrease in insulin concentration was 
found at the two time points (pooled Hedges’s g =-1.358; 95% confidence interval -2.0,-0.6; 
p<0.001) that favoured propranolol use (see Supplemental Digital Content 6, insulin resistance 
forest plot graph, http://links.lww.com/TA/A677; figure 6). 
Hart et al (16) compared insulin dose (units/hour) used to control hyperglycaemic episodes with 
no significant differences between groups.  
Metabolism substrates, hormones, inflammatory markers 
Herndon et al. (18) measured several markers of hypermetabolism after two weeks of 
propranolol treatment, and found no significant changes between groups for serum glucose 
(p=0.67), serum potassium (p=0.05), insulin like growth factor I (p=0.56), growth hormone 
(p=0.26), cortisol (p=0.58) or insulin (p=0.29).  
Changes in plasma triglycerides concentration were analysed in one study (15). A significant 
increase of 54% was found between baseline and post values in those receiving the placebo 
(p<0.0001), while the increase of 12% on triglycerides concentration post propranolol treatment 
was not significant (p=0.12). 
Epinephrine, norepinephrine and dopamine plasma levels examined in a trial (14) were found to 
be elevated in patients randomized to the propranolol group, but the differences compared with 
controls were not statistically significant. 
Jeschke et al (20) analysed cytokine expression profile and found that propranolol significantly 
decreased serum TNF and IL-1 β at one time point when compared with controls (p<0.05). No 
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differences were found for IL-6, IL-8, IL-10, monocyte chemoattractant protein-1 and 
macrophage inflammatory protein 1-β between groups (Table 2). 
Wound healing 
One adult study analysed the effects of propranolol on wound healing (21) and found significant 
differences favouring propranolol use in healing time (p<0.004), time ready to graft (p=0.007), 
area needed for the skin graft (p=0.006) and length of hospital stay (p=0.004) (Table 2). 
Gene expression 
Of ten studies incorporated in this systematic review, two used mRNA expression of genes in 
adipose (15) or muscle (17) tissue after burn injury and propranolol treatment. Barrow et al. (15) 
compared mRNA expression of three genes between control and propranolol groups. 
Comparison of monoamine oxidase-A favoured propranolol (p<0.05) and changes founded in 
osteopontin favoured control group (p<0.05). No significant differences between groups were 
found in the expression of IGF-1. 
Herndon et al (17) reported changes in mRNA expression of HSP70 with differences favouring 
the propranolol group (p<0.05) (Table 2). 
Adverse events 
Mortality 
Three studies (19, 20, 22) used mortality as an outcome measure, two of them in paediatric 
populations (19, 20) and one (22) in adults. No differences in mortality rates were found in any 
of these trials (Table 2). 
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Incidence of sepsis  
Incidence of sepsis was investigated in four trials (16, 18, 20, 22) performed in children and 
adults subjects, and accepted (24, 25) criteria for the diagnosis was stated in three (16, 18, 20). 
Sepsis was not defined in one study (22). No significant differences in sepsis incidence were 
reported in studies involving paediatric or adult populations (Table 2). 
Hypotension  
Of ten studies analysed, only two (18, 19) investigated whether beta blockade caused 
hypotension. No statistically significant differences in mean arterial blood pressure (MAP) were 
found after two weeks of treatment in the first trial (18) (p=0.7). Although Herndon et al (19) 
found a significantly lower mean arterial blood pressure (MAP) in the intervention group at two 
(p=0.01) and four (p=0.01) weeks post institution of treatment, this was not clinically significant. 
Detailed data is shown in Table 2.  
Hart et al (16) reported no clinically relevant hypotension or bronchospasm after propranolol use 
in their sample. 
Four studies incorporated description of adverse events as outcome measures. Three of them (15, 
17, 18) reported that mechanical ventilation was not required in either control and propranolol 
groups except for brief perioperative periods. These trials also reported absence of pneumonia in 
both groups.  
Psychological health 
No studies included in this systematic review incorporated psychological health and particularly 
anxiety or posttraumatic stress disorder measures as outcomes. 
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DISCUSSION 
Beta-adrenergic blockade has been used to improve outcomes in patients suffering burn injuries 
for at least 35 years (5). The American Burn Association Consensus statement in 2013 (26) 
specified beta-blockade as one of the pharmacologic approach to modulate the stress response 
after burns, and recognizing the potential benefits associated with beta-blockade on several 
outcomes related with postburn hypermetabolism. However, they also claimed that a higher level 
of evidence is necessary to accurately address benefits and safety  
This systematic review and meta-analysis has found some limited evidence that there are 
consistent benefits on cardiac function, liver function, metabolic rate, body composition and 
wound healing after adrenergic-blockade treatment following burns. Moreover, evidence found 
from these studies suggests that beta-blocker use is safe and does not cause adverse effects. 
The efficacy of adrenergic blockade on cardiac function outcomes of burned patients has been 
described in a number of studies from the initial observations of Wilmore et al (5) in 1974. Most 
of the trials performed consistently showed a negative chronotropic effect (5, 15-23, 27-29) and 
consequently, the benefits of a reduction of cardiac stress without affecting delivery of oxygen 
(27, 28, 30). This emphasizes the potential role that beta blockade could play in prevention of 
catecholamine-induced cardiac impairment (28, 30). Increased levels of norepinephrine and 
epinephrine have been observed in paediatric burn patients even after two years and sixty days 
respectively (31), and the magnitude of the stress response is related to the size of the burned 
area (32). The non-selective activity of propranolol on β1 and β2 adrenergic receptors 
theoretically counteract the increased levels of catecholamines, by binding to adrenergic 
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receptors and blocking the positive inotropic and chronotropic effect of the sympathetic system 
(33).  
Most of the studies describing effects of propranolol in patients with burns have been performed 
in paediatric populations while a dearth of trials showing effects in adults was noted. In an adult 
population a clinical trial comparing both oral and parenteral route administration has shown 
significant reductions in metabolism and heart rate by both methods (29). Arbabi et al (34) in a 
retrospective cohort study found that pre morbid use of beta blockers improved outcomes and 
mortality in adult burned patients. However, caution should be adopted in accepting the results as 
a requirement for beta blocker use indicated pre morbid co-morbidities.  
Despite absence of evidence describing signalling pathways in burned humans treated with beta-
adrenergic blockade, animal models provide further evidence as to the mechanism of decreased 
hypermetabolism post beta blockers (35). Catecholamines were shown to induce endoplasmic 
reticulum (ER) stress in various cell types through inhibition of the phosphatidylinositol 3-kinase 
(PI3K)/Akt signalling cascade (35). The actions of the catecholamines appeared to be mediated 
through the beta-adrenergic receptors, since blockade of these receptors by the beta-blocker 
propranolol attenuated post burn hepatic ER stress and improved PI3K/Akt signalling (35). 
The assumption that metabolic rate could be controlled under an adrenergic-blockade protocol 
was also examined in this review. A decrease in metabolic rate after propranolol use could be 
explained by two major reasons. 
Breitenstein et al (29) hypothesized that  attenuation of circulatory effects, reducing cardiac work 
and hyperdynamic circulation could explain part of this positive effect. Additionally, elevated 
concentrations of catecholamines cause increased lipolysis and subsequently, increased plasma 
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fatty acid levels (36). Increased triglyceride fatty acid cycling and metabolic rate on children and 
adults post burn injury were further demonstrated by Wolfe et al and a reduction on both cycling 
and metabolic rate by propranolol use was also observed in this population (37). 
Body composition is regarded as a crucial outcome to assess the effects of hypermetabolism on 
muscle, bone and fat tissue (37, 38). The meta-analysis demonstrated efficacy of propranolol in 
decreasing trunk fat, which could lead to a reduction in cardiovascular risk (39) and a positive 
effect on peripheral lean mass.  
Evidence from two studies (17, 18) confirms the positive effect of propranolol treatment on 
muscle protein net balance. Furthermore, one of the studies (18) also investigated the muscle 
protein synthesis and breakdown. Surprisingly, the complete improvement in protein net balance 
can be explained by a large increase in protein synthesis in the propranolol group, with the 
protein breakdown elevated in both treated and untreated patients. Herndon et al (17) found a 
relationship between the increase in muscle protein synthesis and improvements on mRNA 
expression of HSP70 gene, which is involved in muscle metabolism, and this mechanism could 
explain some of the benefits associated with propranolol use. It was also hypothesized that 
propranolol leads to an improvement in the myocyte intracellular recycling of free amino acids 
incorporating more substrates for protein synthesis (18). Finally, the effect of propranolol on 
reduction of metabolic rate could play a role by reducing the substrate oxidation, and avoiding 
energy substrate release from protein and fat stores. 
Benefits related to wound healing were found in an adult population, and is supported by animal 
models (40, 41). Beta blockade with propranolol is claimed to reduce local inflammatory 
response and accelerate the process of wound healing (40). The effect of propranolol stimulating 
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the synthesis of nitric oxide could also assist wound healing by improving collagen deposition 
and myofibroblastic differentiation (40). 
Finally, the data analysed suggests that propranolol does not increase mortality based on data 
from three studies (19, 20, 22) and confirms the neutral effect of this treatment on the incidence 
of sepsis. However, caution should be adopted, as the studies were underpowered for these 
outcomes.  
Limitations 
This systematic review and meta-analysis has some limitations namely the heterogeneity of 
treatment regimens and measurement of outcome measures.  
Although the criteria used for inclusion of studies was strict, the quality of the studies varied. It 
must be noted that none of the selected studies followed a concealment allocation of patients and 
only one (22) explicitly used blinded patients and researchers. However, as most trials were 
paediatric inpatients, blinding of patients and use of a placebo may have been irrelevant. We also 
found incomplete outcome data in seven of ten reports,. For this reason, meta-analysis was 
completed on changes over time for some outcomes and biases within individual studies were 
described, but not included for further analysis. 
Another source of bias could come from the fact that the same research group published eight out 
of ten studies included in this review, with more than 90% of included subjects.  
Additionally these results should not be generalized as most of the trials included only a 
paediatric population.  
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Conclusions 
Current evidence analysed in this report suggest that the use of beta blockers and specifically 
propranolol provide limited benefits on cardiac function, liver function, metabolic rate, body 
composition, muscle protein kinetics and wound healing. There were no reported adverse effects.  
Future trials should incorporate adult populations and also psychological and functional outcome 
measures after adrenergic blockade. 
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Figure Legends 
Figure 1. PRISMA-Based Flow Diagram: description of the literature search process.  
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS 
Med 6(6): e1000097. doi:10.1371/journal.pmed1000097.  
 
Figure 2. Resting Energy Expenditure (% predicted). Changes over 12 months’ time period. 
 
Figure 3. Trunk fat (gr). Changes over 12 months’ time period. 
 
Figure 4. Peripheral Lean Mass (gr). Changes over 12 months’ time period. 
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SDC 5. Heart Rate (% predicted). Change over 12 months’ time period. 
SDC 6. Insulin Resistance. Changes over 2 weeks’ time period. 
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Table 1. Demographics of Selected Studies  
AUTHORS 
POPULATION 
 
AGE 
(Mean years±SD) 
GENDER 
(% Males) 
TBSA 
(%) 
Third Degree Burn (%TBSA) 
Treatment 
Length 
Dose/Route 
Administration 
Akcay,M et al (14) 
(2005) 
CHILDREN/ADULTS 
Control Group n=10 
Propranolol Group 
n=10 
Controls 32.3±3.6 
 
Propranolol 31.4±3.1 
Controls 60% 
 
Propranolol 80% 
Controls 31.8±2.9 
 
Propranolol 30.9±3.4 
Unstated Two weeks 2 mg/kg/day/oral 
Barrow, RE et al  
(15) (2006) 
CHILDREN 
Control Group n=54 
Propranolol Group 
n=44 
Controls 8.4±0.6 
 
Propranolol 6.7±0.6 
Controls 69% 
 
Propranolol 68% 
Controls 59±2 
 
Propranolol 56±2 
Controls 46±3 % 
 
Propranolol 42±3 % 
Unstated 
0.3 to 1 mg/kg every 
four or six hours. Dose 
adjusted to achieve 12 
to 15% reduction on 
HR/enteral 
Hart, DW et al (16) 
(2002) 
CHILDREN 
Control Group n=19 
Propranolol Group 
n=12 
Controls 8.4±1.6 
 
Propranolol 7.0±1.5 
Controls 68% 
 
Propranolol 66% 
Controls 58±4 
 
Propranolol 56±4 
Controls 46±5 % 
 
Propranolol 46±6 % 
10 days 
0.3 to 1 mg/kg every 
four or six hours. Dose 
adjusted to achieve 12 
to 15% reduction on 
HR/oral 
Herndon, DN et al 
(18) (2001) 
CHILDREN 
Control Group n=12 
Propranolol Group 
n=13 
Controls 7.8±1.4 
 
Propranolol 6.6±1.5 
Controls 75% 
 
Propranolol 61% 
Controls 47±4 
 
Propranolol 57±4 
Controls 39±5 % 
 
Propranolol 41±5 % 
Two weeks 
0.33 to 1.05 mg/kg 
every four hours to 
achieve 20% reduction 
on HR/oral 
Herndon, DN et al 
(17) (2003) 
CHILDREN 
Control Group n=23 
Propranolol Group 
n=14 
Controls 10.2±1.1 
 
Propranolol 9,2±1,1 
Controls 64% 
 
Propranolol 66% 
Controls 51±28 
 
Propranolol 61±4,4 
Controls 39±4.9 % 
 
Propranolol 47±6.4% 
Unstated 
0.3 to 1.0 mg/kg every 
four or six hours to 
achieve 10-15% 
reduction on 
HR/enteral 
Herndon, DN et al 
(19) (2012) 
CHILDREN 
Control Group n=89 
Propranolol Group 
n=90 
Controls 7±5 
 
Propranolol 7±5 
Controls 63% 
 
Propranolol 74% 
Controls 57.5±13.5 
 
Propranolol 
55.7±16.5 
Controls 45.6±22.7 % 
 
Propranolol 42,9±24 % 
12 months 
4 mg/kg/day to achieve 
15% reduction on 
HR/not reported 
Jeschke, MG et al 
(20) (2007)  
CHILDREN 
Control Group 
n=143 
Propranolol Group 
n=102 
Controls 7.8±0.4 
 
Propranolol 7.2±0.6 
Unstated 
 
Propranolol 58% 
Controls 55±1 
 
Propranolol 54±2 
Controls 43±2 % 
 
Propranolol 44±3% 
Unstated 
0.5 to 1.5 mg/kg every 
six hours/oral 
Mohammadi, A et 
al  (22) (2009) 
ADULTS 
Control Group n=42 
Propranolol Group 
n=37 
Controls 24.54±12.06 
 
Propranolol 27.71±9.73 
Controls 91% 
 
Propranolol 59% 
Controls 33.61±8.76 
 
Propranolol 
31.42±7.95 
Controls 19.09±6.75 % 
 
Propranolol 17.48±6.09% 
Unstated 
1 to 1.98 mg/kg/day to 
achieve 20% reduction 
on HR/oral 
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Morio, B et al (23) 
(2002) 
CHILDREN/ADULTS 
Control Group n=4 
Propranolol Group 
n=4 
Controls 28.3±22.0 
 
Propranolol 15.1±15.3 
Unstated 
Controls 77.3±12.3 
 
Propranolol 78±19.9 
Controls 70.0±19.8 % 
 
Propranolol 74.3±21.5% 
Three weeks 
2 mg/kg/day to achieve 
25% reduction on 
HR/oral 
Williams, FN et al 
(21) (2011) 
CHILDREN 
Control Group 
n=215 
Propranolol Group 
n=125 
Controls 8±5 
 
Propranolol 7±5 
Controls 59% 
 
Propranolol 71% 
Controls 55±15 
 
Propranolol 55±15 
Controls 40±24 % 
 
Propranolol 42±22% 
30 ± 20 days 
4 mg/kg/day to achieve 
15% reduction on 
HR/enteral 
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Table 2. Details and Results on Outcomes for Selected Studies 
 
OUTCOME AUTHORS RESULTS SIGNIFICANCE FAVORS 
Heart Rate (description) Herndon et al (2001) 
(18) 
Decrease of 20 % 
compared with baseline 
and control group 
p=0.001 Propranolol 
 Williams et al (2011) 
(21) 
Decrease of 18% 
compared to control group 
p<0.001 Propranolol 
Heart Rate (% Predicted) Herndon et al (2012) 
(19) 
168±14 vs 152±14 (two 
weeks) 
p<0.001 Propranolol 
  162±17 vs 150±17 (four 
weeks) 
p<0.001 Propranolol 
  127±19 vs 116±19 (six 
months) 
p<0.01 Propranolol 
  119±16 vs 110±16 (twelve 
months) 
p<0.01 Propranolol 
Heart Rate (mean bpm) Mohammadi et al 
(2009) (22) 
116.45±12.75 vs 
83.91±13.19 
p<0.001 Propranolol 
 
 Morio et al (2002) (23) 135.2±13.6 vs 123.0±22.9 
 
p<0.05 Propranolol 
 
 
OUTCOME AUTHORS RESULTS SIGNIFICANCE FAVORS 
     
Cardiac Output 
 (% predicted) 
Williams et al (2011) 
(21) 
158±8 vs 135±5 p<0.05 Propranolol 
 
OUTCOME  AUTHORS RESULTS SIGNIFICANCE FAVORS 
     
Increased Liver Size  
(incidence) 
Barrow et al (2006) (15) 79.59% vs 13.88% p<0.01 Propranolol 
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OUTCOME  AUTHORS RESULTS SIGNIFICANCE FAVORS 
Resting Energy 
Expenditure  
 
(mean change in 
kcal/day) 
Herndon et al (2001) (18) 140±67 vs -422±197 p=0.001 Propranolol 
 
Oxygen 
Cosumption 
(ml/min) 
 
Herndon et al (2001) (18) 
 
236±33 vs 187±24 
 
p=0.002 
 
Propranolol 
 
OUTCOME  AUTHORS RESULTS SIGNIFICANCE FAVORS 
Muscle Protein Net 
Balance 
(nmol Phe/min/100cc leg)  
Herndon et al (2001) (18) -42±16 vs 35±11 p=0.001 Propranolol 
 
 Herndon et al (2003) (17) -14.3±12.9 vs 69.3±34.9 p=0.012 Propranolol 
 
Muscle Protein Synthesis 
 (nmol Phe/min/100cc 
leg) 
Herndon et al (2001) (18) 142±34 vs 337±61 p=0.07 NS 
 
Muscle Protein 
Breakdown 
(nmol Phe/min/100cc leg)   
Herndon et al (2001) (18) 184±30 vs 287±48 p=0.2 NS 
 
 
 
OUTCOME AUTHORS RESULTS SIGNIFICANCE FAVORS 
     
Lean Body Mass Barrow et al (2006) (15) No significant change between 
groups 
NS NS 
 Herndon et al (2001) (18) 73.5±1.5 vs 79.1±1.2 p=0.01 Propranolol 
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OUTCOME  AUTHORS RESULTS SIGNIFICANCE FAVORS 
     
Fat Free Mass Barrow et al (2006) (15) No significant change between 
groups 
NS NS 
 Herndon et al (2001) (18) 9% vs 1% lost on FFM p=0.003 Propranolol 
 
Total Body Fat  Barrow et al (2006) (15) 4% vs 6% increase on TBF NS NS 
 
Trunk Fat 
(% Change)  
Barrow et al (2006) (15) 11% vs 16% increase on Trunk 
Fat 
NS NS 
 
OUTCOME  AUTHORS RESULTS SIGNIFICANCE FAVORS 
     
Insulin Resistance 
(µU/ml x fasting 
glucose value) 
Ackay et al (2005) (14) 23.28±12.43 vs 18.31±9.91  
(one week) 
Unstated NS 
 Ackay et al (2005) (14) 24.27±13.68 vs 14.02±7.52 
(two weeks) 
p<0.05 Propranolol 
 
Serum glucose 
concentration 
(mg/dl)  
Herndon et al (2001) (18) 114±4 vs 115±3 p=0.67 NS 
Serum potassium 
concentration 
(mg/dl) 
Herndon et al (2001) (18) 3.72±0.08 vs 3.76±0.13 p=0.05 NS 
Insulin like 
Growth factor I 
(ng/ml) 
Herndon et al (2001) (18)  123±16 vs 112±19 p=0.56 NS 
Plasma 
Triglycerides 
Concentration 
(% Change)  
Barrow et al (2006) (15) 54 vs 12 p<0.001 Propranolol 
 
Growth Hormone 
(ng/dl)  
Herndon et al (2001) (18) 2.0±0.9 vs 1.1±0.4 p=0.26 NS 
Cortisol (µg/dl) Herndon et al (2001) (18) 10.2±2.3 vs 9.8±1.3 
 
p=0.58 NS 
Insulin  Herndon et al (2001) (18) 77.3±20.5 vs 104±52 p=0.29 NS 
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(µIU/ml) 
Insulin dose 
(units/hour) 
Hart et al (2002) (16) 1.0±0.8 vs 1.5±1.5 NS NS 
Serum TNF 
(pg/ml) 
Jeschke et al (2007) (20) Significant decrease at one time 
point 
p<0.05 Propranolol 
Serum IL-
1β(pg/ml) 
Jeschke et al (2007) (20) Significant decrease at one time 
point 
p<0.05 Propranolol 
Serum IL-6 
(pg/ml) 
Jeschke et al (2007) (20) No significant difference 
between groups 
NS NS 
Serum IL-6 
(pg/ml) 
Jeschke et al (2007) (20) No significant difference 
between groups 
NS NS 
Serum IL-8 
(pg/ml) 
Jeschke et al (2007) (20) No significant difference 
between groups 
NS NS 
Serum IL-10 
(pg/ml) 
Jeschke et al (2007) (20) No significant difference 
between groups 
NS NS 
Serum monocyte 
chemoattractant 
protein-1 (pg/ml) 
Jeschke et al (2007) (20) No significant difference 
between groups 
NS NS 
Serum 
macrophage 
inflammatory 
protein 1- β 
(pg/ml) 
Jeschke et al (2007) (20) No significant difference 
between groups 
NS NS 
 
OUTCOME  AUTHORS RESULTS SIGNIFICANCE FAVORS 
Healing Time 
(days)  
Mohammadi et al. (2009) (22) 21.52 vs 16.13±7.4 p<0.004 Propranolol 
 
Time ready for 
graft (days)  
 
Mohammadi et al. (2009) (22) 33.46±9.17 vs 28.23±8.43 p=0.007 Propranolol 
Area needed skin 
graft (%TBSA) 
Mohammadi et al. (2009) (22) 18.72 vs 13.75 
 
p=0.006 Propranolol 
Hospital stay 
period (days) 
 
Mohammadi et al. (2009) (22) 30.95±8.44 vs 24.41±8.11 p=0.004 Propranolol 
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OUTCOME  AUTHORS RESULTS SIGNIFICANCE FAVORS 
Mean Arterial 
Blood Pressure 
(mm Hg)  
Herndon et al. (2001) (18) 81±3 vs 74±4 p=0.7 NS 
 
 Herndon et al. (2012) (19) 78±8 vs 73±8 
(two weeks) 
p=0.01 Control  
  79±8 vs 74±8 
(four weeks) 
p=0.01 Control  
  81±9 vs 77±9 
(6 months) 
NS NS 
  78±8 vs 77±8 
(12 months) 
NS NS 
     
Sepsis 
(Incidence)  
Hart et al. (2002) (16) 4/19 (21.05%) vs 1/12 (8.33%) NS NS 
 
 Herndon et al. (2001) (18) 3/12 (25%) vs 4/13 (30.7%) 
 
p=1.0 NS 
 Jeschke et al. (2007) (20) 14/143 (9.79%) vs 7/102 (6.86%) 
 
NS NS 
 Mohammadi et al. (2009) (22) 12/42 (28.57%) vs 9/37 (24.32%) 
 
p=0.18 NS 
Mortality 
(Incidence) 
Herndon et al. (2012) (19) 6/89 (6.74%) vs 4/90 (4.44%) 
 
p=0.72 NS 
 Jeschke et al. (2007) (20) 14/143 (9.79%) vs 7/102 (6.86%) 
 
NS NS 
 Mohammadi et al. (2009) (22) 12/42 (28.57%) vs 9/37 (24.32%) p=0.92 NS 
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OUTCOME  AUTHORS RESULTS SIGNIFICANCE FAVORS 
Clinical Consequences 
(Description)  
Barrow et al. (2006) (15) Neither requirement of MV (except 
for brief perioperative periods) nor 
pneumonia in both control and 
propranolol groups 
NS NS 
 
 Hart et al. (2002) (16) No clinically relevant hypotension 
or bronchospasm 
NS NS 
 Herndon et al. (2001) (18) Neither requirement of MV (except 
for brief perioperative periods) nor 
pneumonia in both control and 
propranolol groups 
NS NS 
 Herndon et al. (2003) (17) Neither requirement of MV (except 
for brief perioperative periods) nor 
pneumonia in both control and 
propranolol groups 
NS NS 
 
OUTCOME  AUTHORS RESULTS SIGNIFICANCE FAVORS 
Monoamine Oxidase-A Gene 
Expression (mRNA/β-actin 
ratio) 
Barrow et al. (2006) (15) 0.58±0.31 vs 1.91±0.21 p<0.05 Propranolol 
 
Osteopontin Gene Expression 
(mRNA/β-actin ratio) 
Barrow et al. (2006) (15) 2.33±0.09 vs 0.65±0.02 p<0.05 Control 
 
IGF-1 Gene Expression 
(mRNA/β-actin ratio) 
Barrow et al. (2006) (15) 1.1±0.28 vs 0.91±0.019 NS NS 
HSP70 Gene Expression 
(mRNA/β-actin ratio) 
Herndon et al. (2003) (17) 0.54±0.01 VS 1.21±0.06 p<0.05 Propranolol 
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Table 3. Details and Results on Outcomes for Selected Studies 
 
OUTCOME AUTHORS RESULTS SIGNIFICANCE FAVORS 
Heart Rate (description) Herndon et al (2001) 
(18) 
Decrease of 20 % 
compared with baseline 
and control group 
p=0.001 Propranolol 
 Williams et al (2011) 
(21) 
Decrease of 18% 
compared to control group 
p<0.001 Propranolol 
Heart Rate (% Predicted) Herndon et al (2012) 
(19) 
168±14 vs 152±14 (two 
weeks) 
p<0.001 Propranolol 
  162±17 vs 150±17 (four 
weeks) 
p<0.001 Propranolol 
  127±19 vs 116±19 (six 
months) 
p<0.01 Propranolol 
  119±16 vs 110±16 (twelve 
months) 
p<0.01 Propranolol 
Heart Rate (mean bpm) Mohammadi et al 
(2009) (22) 
116.45±12.75 vs 
83.91±13.19 
p<0.001 Propranolol 
 
 Morio et al (2002) (23) 135.2±13.6 vs 123.0±22.9 
 
p<0.05 Propranolol 
 
 
OUTCOME AUTHORS RESULTS SIGNIFICANCE FAVORS 
     
Cardiac Output 
 (% predicted) 
Williams et al (2011) 
(21) 
158±8 vs 135±5 p<0.05 Propranolol 
 
OUTCOME  AUTHORS RESULTS SIGNIFICANCE FAVORS 
     
Increased Liver Size  
(incidence) 
Barrow et al (2006) (15) 79.59% vs 13.88% p<0.01 Propranolol 
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OUTCOME  AUTHORS RESULTS SIGNIFICANCE FAVORS 
Resting Energy 
Expenditure  
 
(mean change in 
kcal/day) 
Herndon et al (2001) (18) 140±67 vs -422±197 p=0.001 Propranolol 
 
Oxygen 
Cosumption 
(ml/min) 
 
Herndon et al (2001) (18) 
 
236±33 vs 187±24 
 
p=0.002 
 
Propranolol 
 
OUTCOME  AUTHORS RESULTS SIGNIFICANCE FAVORS 
Muscle Protein Net 
Balance 
(nmol Phe/min/100cc leg)  
Herndon et al (2001) (18) -42±16 vs 35±11 p=0.001 Propranolol 
 
 Herndon et al (2003) (17) -14.3±12.9 vs 69.3±34.9 p=0.012 Propranolol 
 
Muscle Protein Synthesis 
 (nmol Phe/min/100cc 
leg) 
Herndon et al (2001) (18) 142±34 vs 337±61 p=0.07 NS 
 
Muscle Protein 
Breakdown 
(nmol Phe/min/100cc leg)   
Herndon et al (2001) (18) 184±30 vs 287±48 p=0.2 NS 
 
 
 
OUTCOME AUTHORS RESULTS SIGNIFICANCE FAVORS 
     
Lean Body Mass Barrow et al (2006) (15) No significant change between 
groups 
NS NS 
 Herndon et al (2001) (18) 73.5±1.5 vs 79.1±1.2 p=0.01 Propranolol 
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OUTCOME  AUTHORS RESULTS SIGNIFICANCE FAVORS 
     
Fat Free Mass Barrow et al (2006) (15) No significant change between 
groups 
NS NS 
 Herndon et al (2001) (18) 9% vs 1% lost on FFM p=0.003 Propranolol 
 
Total Body Fat  Barrow et al (2006) (15) 4% vs 6% increase on TBF NS NS 
 
Trunk Fat 
(% Change)  
Barrow et al (2006) (15) 11% vs 16% increase on Trunk 
Fat 
NS NS 
 
 
OUTCOME  AUTHORS RESULTS SIGNIFICANCE FAVORS 
     
Insulin Resistance 
(µU/ml x fasting 
glucose value) 
Ackay et al (2005) (14) 23.28±12.43 vs 18.31±9.91  
(one week) 
Unstated NS 
 Ackay et al (2005) (14) 24.27±13.68 vs 14.02±7.52 
(two weeks) 
p<0.05 Propranolol 
 
Serum glucose 
concentration 
(mg/dl)  
Herndon et al (2001) (18) 114±4 vs 115±3 p=0.67 NS 
Serum potassium 
concentration 
(mg/dl) 
Herndon et al (2001) (18) 3.72±0.08 vs 3.76±0.13 p=0.05 NS 
Insulin like 
Growth factor I 
(ng/ml) 
Herndon et al (2001) (18)  123±16 vs 112±19 p=0.56 NS 
Plasma 
Triglycerides 
Concentration 
(% Change)  
Barrow et al (2006) (15) 54 vs 12 p<0.001 Propranolol 
 
Growth Hormone 
(ng/dl)  
 
Herndon et al (2001) (18) 2.0±0.9 vs 1.1±0.4 p=0.26 NS 
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Cortisol (µg/dl) Herndon et al (2001) (18) 10.2±2.3 vs 9.8±1.3 
 
p=0.58 NS 
Insulin  
(µIU/ml) 
Herndon et al (2001) (18) 77.3±20.5 vs 104±52 p=0.29 NS 
Insulin dose 
(units/hour) 
Hart et al (2002) (16) 1.0±0.8 vs 1.5±1.5 NS NS 
Serum TNF 
(pg/ml) 
Jeschke et al (2007) (20) Significant decrease at one time 
point 
p<0.05 Propranolol 
Serum IL-
1β(pg/ml) 
Jeschke et al (2007) (20) Significant decrease at one time 
point 
p<0.05 Propranolol 
Serum IL-6 
(pg/ml) 
Jeschke et al (2007) (20) No significant difference 
between groups 
NS NS 
Serum IL-6 
(pg/ml) 
Jeschke et al (2007) (20) No significant difference 
between groups 
NS NS 
Serum IL-8 
(pg/ml) 
Jeschke et al (2007) (20) No significant difference 
between groups 
NS NS 
Serum IL-10 
(pg/ml) 
Jeschke et al (2007) (20) No significant difference 
between groups 
NS NS 
Serum monocyte 
chemoattractant 
protein-1 (pg/ml) 
Jeschke et al (2007) (20) No significant difference 
between groups 
NS NS 
Serum 
macrophage 
inflammatory 
protein 1- β 
(pg/ml) 
Jeschke et al (2007) (20) No significant difference 
between groups 
NS NS 
 
 
OUTCOME  AUTHORS RESULTS SIGNIFICANCE FAVORS 
Healing Time 
(days)  
Mohammadi et al. (2009) (22) 21.52 vs 16.13±7.4 p<0.004 Propranolol 
 
Time ready for 
graft (days)  
 
Mohammadi et al. (2009) (22) 33.46±9.17 vs 28.23±8.43 p=0.007 Propranolol 
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Area needed skin 
graft (%TBSA) 
Mohammadi et al. (2009) (22) 18.72 vs 13.75 
 
p=0.006 Propranolol 
Hospital stay 
period (days) 
 
Mohammadi et al. (2009) (22) 30.95±8.44 vs 24.41±8.11 p=0.004 Propranolol 
 
 
OUTCOME  AUTHORS RESULTS SIGNIFICANCE FAVORS 
Mean Arterial 
Blood Pressure 
(mm Hg)  
Herndon et al. (2001) (18) 81±3 vs 74±4 p=0.7 NS 
 
 Herndon et al. (2012) (19) 78±8 vs 73±8 
(two weeks) 
p=0.01 Control  
  79±8 vs 74±8 
(four weeks) 
p=0.01 Control  
  81±9 vs 77±9 
(6 months) 
NS NS 
  78±8 vs 77±8 
(12 months) 
NS NS 
     
Sepsis 
(Incidence)  
Hart et al. (2002) (16) 4/19 (21.05%) vs 1/12 (8.33%) NS NS 
 
 Herndon et al. (2001) (18) 3/12 (25%) vs 4/13 (30.7%) 
 
p=1.0 NS 
 Jeschke et al. (2007) (20) 14/143 (9.79%) vs 7/102 (6.86%) 
 
NS NS 
 Mohammadi et al. (2009) (22) 12/42 (28.57%) vs 9/37 (24.32%) 
 
p=0.18 NS 
Mortality 
(Incidence) 
Herndon et al. (2012) (19) 6/89 (6.74%) vs 4/90 (4.44%) 
 
p=0.72 NS 
 Jeschke et al. (2007) (20) 14/143 (9.79%) vs 7/102 (6.86%) 
 
NS NS 
 Mohammadi et al. (2009) (22) 12/42 (28.57%) vs 9/37 (24.32%) p=0.92 NS 
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OUTCOME  AUTHORS RESULTS SIGNIFICANCE FAVORS 
Clinical Consequences 
(Description)  
Barrow et al. (2006) (15) Neither requirement of MV (except 
for brief perioperative periods) nor 
pneumonia in both control and 
propranolol groups 
NS NS 
 
 Hart et al. (2002) (16) No clinically relevant hypotension 
or bronchospasm 
NS NS 
 Herndon et al. (2001) (18) Neither requirement of MV (except 
for brief perioperative periods) nor 
pneumonia in both control and 
propranolol groups 
NS NS 
 Herndon et al. (2003) (17) Neither requirement of MV (except 
for brief perioperative periods) nor 
pneumonia in both control and 
propranolol groups 
NS NS 
 
OUTCOME  AUTHORS RESULTS SIGNIFICANCE FAVORS 
Monoamine Oxidase-A Gene 
Expression (mRNA/β-actin 
ratio) 
Barrow et al. (2006) (15) 0.58±0.31 vs 1.91±0.21 p<0.05 Propranolol 
 
Osteopontin Gene Expression 
(mRNA/β-actin ratio) 
Barrow et al. (2006) (15) 2.33±0.09 vs 0.65±0.02 p<0.05 Control 
 
IGF-1 Gene Expression 
(mRNA/β-actin ratio) 
Barrow et al. (2006) (15) 1.1±0.28 vs 0.91±0.019 NS NS 
HSP70 Gene Expression 
(mRNA/β-actin ratio) 
Herndon et al. (2003) (17) 0.54±0.01 VS 1.21±0.06 p<0.05 Propranolol 
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INTRODUCTION 
Rationale, research question and objective 
 
Burns are a common type of traumatic injuries requiring nearly eleven million medical attentions 
throughout the world in 2004 (1). Although mortality has been decreased over the last decades (2), 
studies have been demonstrated that hypermetabolic response following severe burns still cause 
several detrimental effects twelve months (3) and even three years (4) after injury. Mediated by raised 
catecholamines concentration (5), this chronic impairment is a major problem characterized by 
increased metabolic rate (6), increased heart rate and cardiac stress (7), increased oxygen consumption 
(8), changes in body composition (3), and higher muscle (3) and bone (6) catabolism. Variable incidence 
of sepsis (9) and mortality (2) have been also reported in burned patients. 
As catecholamines are primary mediators of the hypermetabolic response post burns (5), adrenergic 
blockade has been extensively used to attenuate catecholamine-induced changes after severe thermal 
injuries (5, 7, 10-22).  
However, there has not been a systematic evaluation of benefits associated with propranolol use and 
safety of such therapeutic intervention. Therefore, the purpose of the systematic review proposed is to 
assess the quality of evidence supporting the efficacy and safety of use of adrenergic blockade on adult 
and children affected by burn injuries. 
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METHODS 
Eligibility 
A population, intervention, comparison and outcomes (PICO) approach was created to develop an 
inclusion/exclusion criteria. In summary, PICO’s approach will be considered as follows: 
 Population: adults or children in any phase of burn injury. Animal model experiments 
and studies based in patients with toxic epidermal necrolysis syndrome will be excluded. 
 Intervention: Beta Blockers in general or propranolol as specific drug. Adrenergic 
blockade should be used as the exclusive intervention and consequently, studies 
reporting combined intervention will be excluded.  
 Comparison: no comparison will be made with any other treatment. 
 Outcomes:  any relevant endpoint showing changes in efficacy and safety after 
intervention will be considered to include. 
 
Study design: We will select systematic reviews, randomized controlled trials and non-randomized 
controlled trials as designs to be included in this study. Consequently, we will exclude any study with 
retrospective deign, non-controlled trials (including studies using historical controls) and narrative 
reviews.  
Language: Eligibility will be restricted to articles published in English, French and Spanish. 
Time: studies published from database inception to December 2014 will be considered. 
Sources: Searching will be restricted to electronic databases and manual search from references of 
selected articles. We will search on Medline via OVID, Pubmed, CINAHL, Cochrane Library, Embase and 
Web of Science. 
Search strategy 
A search strategy was created and tested. For Population, the term “burns” (truncation) OR burns 
(MeSH) OR “thermal injury” OR “burn injury” will be used as broad as possible for each database. For 
Intervention, the terms “Beta Blockers” (truncation) OR “Adrenergic Beta-Antagonists” (truncation) OR 
“Adrenergic Beta-Antagonists” (MeSH) OR “Propranolol” (truncation) will be used for each database. 
Searching will be performed using the following combination (when possible) 
a) Keywords for population combined by “OR” command: “burns” (truncation) OR 
burns (MeSH) OR “thermal injury” OR “burn injury” 
b) Keywords for intervention combined by “OR” command: “Beta Blockers” 
(truncation) OR “Adrenergic Beta-Antagonists” (truncation) OR “Adrenergic Beta-
Antagonists” (MeSH) OR “Propranolol” (truncation) 
c) Results for Population keywords and Intervention keywords will be combined using 
the “AND” command. 
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Keywords will be searched in a broadly approach, but to focus the searching process, four limits will be 
used: 
a. As interest is focused in Clinical Trials, limitation to studies performed in Humans will be 
used according to possibilities offered for each database. 
b. As quality of studies need to be controlled, limitation to type of study will be used 
selecting “Meta-Analysis”, “Systematic Review”, “Randomized Controlled Trials”, 
“Controlled Clinical Trials” and “Reviews” as a limitation criteria. 
c. Publication date from inception to 2014/12/31 
d. Language limited to English, French and Spanish. 
 
Selection Process: The EndNote™ X7 reference manager software (Thomson Reuters, Toronto ON, 
Canada) will be used for import references, discard duplicates and manage the references obtained in 
each stage of the selection process. 
Two reviewers (OF and JP) will conduct independently, a title and abstract screening for eligibility. After 
abstract screening, selected studies will be retrieved for a second-stage manuscript full-text review and 
application of inclusion criteria. Divergences will be resolved by discussion and a third reviewer. A data 
collection sheet will be constructed, tested and refined. Information will be extracted of each included 
study retrieving data regarding a) characteristics of participants (age, total body surface area (%TBSA) 
affected by burns, time from injury, third degree burn percentage, gender, etc); b) intervention (drug, 
dose, duration, frequency, administration via) and c) Outcomes measures and results. If necessary, 
authors will be contacted via email to ask for further information. 
Risk of bias analysis 
To appraise the risk of bias on selected reports, two reviewers (OF, JP) working independently, will use a 
modified and updated version of the  method for assessing the quality of Randomized Controlled Trials 
published by Chalmers et al. (1981)(23).  
Data Analysis 
A quantitative approach will be used to analyse the data at a group level, if there were a sufficient 
number of trials with homogenous outcomes. To compare results between trials, for continuous 
outcomes the unbiased effect size estimators (Hedges g) with 95% confidence intervals will be 
calculated, using Comprehensive Meta-analysis™ software. Dichotomous outcomes will be expressed as 
risk ratios with 95% confidence intervals. The data will be pooled using the fixed effects model, however 
when heterogeneity was statistically significant (Q statistic p<0.01), the data will be re-analysed using 
the random effects model.  
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SDC 2. PRISMA 2009 Checklist. Efficacy and safety of adrenergic blockade post-burns. 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  Title 
Page 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
Abstract 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  1,2 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
2 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
2 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
2 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
2 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
2, 3, SDC 
3  
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
3 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
3 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
3 
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Section/topic  
# Checklist item  
Reported 
on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
N/A 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
N/A 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
4, Figure 
1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
4, 5, 
Table 1 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  5, SDC 2 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
5-12, 
Table 3 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  5-12 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  N/A 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  N/A 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
12-15 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
15, 16 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
3 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  3, 4 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I
2
) for each meta-analysis.  
3, 4 
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Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  16 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
Title 
Page 
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SDC 3. Search Strategy 
The efficacy and safety of adrenergic blockade post burn injury: A systematic review and 
meta-analysis 
 
Search strategy: PubMed 
1. burns* 
2. burns [MeSH Terms] 
3. “thermal injury” 
4. “burn injury” 
5. #1 OR #2 OR #3 OR #4 
6. beta blockers* 
7. adrenergic beta-antagonists 
8. adrenergic beta-antagonists [MeSH Terms] 
9. propranolol* 
10. #6 OR #7 OR #8 OR #9 
11. #5 AND #10 
12. (#5 AND #10) Filters: Controlled Clinical Trials; Meta-analysis; Randomized Controlled 
Trial; Review; Systematic Review 
13. (#12) Filters: Humans 
14. (#13) Filters: publication date to 2014/12/31 
15. (#14) Filters: English; French; Spanish 
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SDC 4. Risk of Bias in individual selected studies 
 
SDRL=Selection Description and Reject Log; RSG=Random Sequence Generation; AC=Allocation Concealment; Bpatients=Blinding of Patients; Placebo: Use of Placebo in Controls; 
Bpersonnel=Blinding of Personnel; ENES=Estimation of numbers, endpoints, significance; ASA=Appropriate Statistical Analysis; COD=Complete Outcome Data; CNSR=Complete 
Non-Selective Reporting. 
 
AUTHORS  /   ITEMS SDRL RSG AC BPatients Placebo BPersonnel ENES ASA COD CNSR 
Akcay,M et al  
(2005)(14) 
NO NO NO NO NO NO NO NO YES YES 
Barrow, RE et al.  
(2006)(15) 
YES YES NO NO YES NO NO YES NO YES 
Hart, DW et al.  
(2002)(16) 
YES YES NO NO NO NO NO YES NO YES 
Herndon, DN et al. 
(2001)(18) 
YES YES NO NO NO NO NO YES NO YES 
Herndon, DN et al. 
(2003)(17) 
YES YES NO NO YES NO NO YES NO NO 
Herndon, DN et al. 
(2012)(19) 
YES YES NO NO NO NO NO YES YES YES 
Jeschke, MG et al. 
(2007)(20) 
YES YES NO NO YES NO NO YES NO YES 
Mohammadi, A et al. 
(2009)(22) 
YES YES NO YES YES YES NO YES YES YES 
Morio, B et al. 
 (2002)(23) 
NO YES NO NO NO NO NO YES NO YES 
Williams, FN et al. 
(2011)(21) 
YES YES NO NO NO NO NO YES NO YES 
SUMMARY 
(Overall Percentage) 
80% 90% 0% 10% 40% 10% 0% 90% 30% 90% 
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SDC 5. Heart Rate (% predicted). Change over 12 months’ time period. 
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SDC 6. Insulin Resistance. Changes over 2 weeks’ time period. 
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